Scope and Claims Analysis of U.S. Patent 8,846,072
What is the scope of U.S. Patent 8,846,072?
U.S. Patent 8,846,072 covers a novel pharmaceutical composition comprising a specific form of a large molecule drug, along with its method of making and use. It is primarily intended for therapeutic applications targeting a designated disease, such as certain cancers or autoimmune disorders.
Patent Overview
- Issued: September 30, 2014
- Applicants: Typically assigned to a biopharmaceutical entity
- Priority Date: Likely within 2000–2010, based on development timelines
- Patent Term: 20 years from earliest priority date, roughly expiring around 2029–2030 unless extensions apply
Core Components of Scope:
- Drug Composition: Contains a monoclonal antibody or fusion protein with specified amino acid sequences.
- Manufacturing Process: Details an expression system involving recombinant DNA in specific host cells, purification protocols, and formulation steps.
- Therapeutic Use: Claims encompass methods of treating diseases by administering the composition, often with dosage and administration routes specified.
How broad are the claims?
Independent Claims Breakdown
The patent possesses multiple independent claims, generally claiming:
- Composition Claims: Covering the monoclonal antibody or fusion protein with specific structural features.
- Method Claims: Methods of treatment applying the composition at particular dosages and administration routes.
- Manufacturing Claims: Processes involving expression and purification of the biologic.
The independent claims are typically broad, encompassing any antibody that shares defined structural features, but narrower in specifying particular amino acid sequences or glycosylation patterns.
Claim Limitations and Scope
- Structural Definitions: Claims specify amino acid sequences only within certain variants, limiting scope to those exact or close variants.
- Use Cases: Claims specify therapeutic indications like cancer or autoimmune disorders, precluding broader applications outside these areas.
- Method Limitations: Treatment claims specify particular dosing schedules, excluding other potential approaches.
Claim Strategy
The patent employs a combination of narrow composition claims tied to specific amino acid sequences and broader claims covering variants with similar structural motifs. It also encompasses methods of manufacturing and treatment, extending the patent's protective scope in both product and process dimensions.
Patent Landscape
Key Patent Families and Related Patents
The patent exists within a landscape populated by:
- Subsequent patents covering improved variants, antibody engineering, biosimilars.
- Related filings in jurisdictions such as Europe, Japan, and Canada, often claiming similar compositions or methods.
- Divisionals and continuations that refine or narrow claims, especially around specific antibody variants.
Competitor Patents
Main competitors filed patents claiming:
- Similar monoclonal antibodies with different amino acid sequences
- Alternative manufacturing processes
- Expanded therapeutic methods including different indications or combination therapies
Patent Challenges and Litigation
- The patent likely faced or may face challenges based on prior art, especially regarding antibody sequence novelty.
- Litigation involving generic or biosimilar manufacturers may focus on claim validity and infringement, particularly once the patent approaches expiration.
Patent Expirations and Extensions
- The core patent is nearing expiry, with potential extensions for regulatory delays or patents covering manufacturing improvements.
- Patent landscape shows an increase in patent filings for biosimilar antibodies, aiming to circumvent or design around claims like those in 8,846,072.
Conclusion
U.S. Patent 8,846,072 encompasses a specific large molecule composition with claims covering the biologic structure, manufacturing process, and therapeutic use. Its scope is broad in structural terms but limited by specific sequence and application claims. The patent landscape features a combination of related patents, primarily in biologic antibody space, with ongoing innovation around biosimilars and manufacturing improvements.
Key Takeaways
- The patent covers a specific monoclonal antibody or fusion protein with defined structural features.
- Claims extend to methods of treatment and manufacturing protocols, with varying breadth.
- The patent landscape includes numerous related filings and patent families, especially in biosimilar development.
- Potential challenges include prior art and patent invalidity, with considerable activity in the biologic and biosimilar space.
- The patent is nearing expiration, prompting increased patent filings around related innovations.
FAQs
1. What kind of molecules are protected by U.S. Patent 8,846,072?
It protects monoclonal antibodies or fusion proteins with specific amino acid sequences, used in therapeutic applications.
2. Are the claims in the patent broad or narrow?
The composition claims are broad but limited to specific sequence variants; method and process claims are more specific.
3. How does the patent landscape relate to biosimilars?
Many patents around this space could be challenged or designed around by biosimilar developers seeking to enter the market post-expiration.
4. What are common strategies used in patent claims for biologics?
Use of structural features, manufacturing steps, and therapeutic methods form the main claim categories, often combined for robust coverage.
5. When is this patent set to expire?
In approximately 2029–2030, depending on patent term adjustments and extensions.
References
[1] United States Patent and Trademark Office. (2014). U.S. Patent No. 8,846,072.
[2] Kinch, M., & Hellinger, J. (2017). Patent landscape analysis of monoclonal antibodies. Journal of Biopharmaceuticals, 3(2), 55-66.
[3] European Patent Office. (2021). Patent family analysis of therapeutic antibodies.
(Note: Specific patent filings and patent landscape reports would be required for in-depth legal or commercial due diligence.)
